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 Abstract    
Aim of the study: Aim of the study was the assessment of prognostic factors in the group of primary invasive 
vaginal carcinoma (PIVC) patients subjected to radical radiation therapy.
Material and methods: The analysis was performed for the group of 152 PIVC patients treated with intracavitary 
brachytherapy alone (16.5%), the combination of brachytherapy and external radiotherapy (78.9%), or external 
radiotherapy alone (4.6%). The relationship was investigated between treatment outcome and the following de-
mographic, clinical and histopathological features: age, duration of pathological symptoms, number of births given, 
prior hysterectomy, haemoglobin level, Karnofsky performance status score, primary tumour location in vagina, 
length of vagina involved, FIGO stage, gross appearance, histological type, and tumour grade.
Results: Five-year disease-free survival was observed in 46.1% of the patients (70/152). Patients below 60 years 
of age, with Karnofsky score of 80-90, diagnosed with PIVC in stage I0 or II0, and with tumour of grade G1 or G2 
had significantly higher 5-year disease-free survival. Multifactoral analysis showed that age below 60 and FIGO 
stage I0 and II0 are independent favourable prognostic factors.
Conclusions: The independent prognostic factors in PIVC patients treated with radical radiotherapy are patient 
age and FIGO stage. 
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Introduction
Primary	 invasive	 vaginal	 carcinoma	 (PIVC)	 is	 a	 disease	
of	 a	 rare	 occurrence	 accounting	 for	 1-2%	 of	 gynaecologic	
malignancies	 and	 0.1-0.2%	of	 all	malignant	 neoplasms	 [1-14].	
In	 Poland	 in	 2006,	 there	 were	 87	 newly	 diagnosed	 cases	 of	
PIVC	notified,	which		comprised	0.1%	of	the	overall	incidence	of	
malignant	neoplasm	(standardized	rate		of	0.2/100	000),	and	67	
deaths,	being	0.2%	of	the	total	number	of	deaths	due	to	malignant	
neoplasm	[15].	
The	treatment	of	choice	for	most	of	PIVC	patients	is	radiation	
therapy	 administered	 as	 intracavitary	 brachytherapy,	 interstitial	
brachytherapy	and	external	 radiotherapy	[2,	1,	4,	6,	 -9,	12,	13,	
16,	-20,	47,	52].	
Aim of the study
Due	to	PIVC	rare	occurrence,	some	aspects	of	radiotherapy	
of	the	patients	are	still	the	subject	of	controversy	in	the	literature.	
Aim	of	the	presented	study	was	to	analyze	one	of	them,	namely	
the	 issue	 of	 prognostic	 factors	 in	 the	 group	 of	 PIVC	 patients	
subjected		to	radical	radiation	therapy.
Material and methods
Between	 1967	 and	 2005,	 173	 PIVC	 patients	 were	 treated	
in	 COOK;	 13	 (7.5%)	 received	 surgical	 treatment	 alone	 or	 in	
combination	 with	 radiotherapy;	 8	 (4.6%),	 palliative	 radio-	 or	
chemotherapy;	and	152	(87.9%),	radical	radiation	therapy	alone.
The	subject	of	further	detailed	analysis	is	the	group	of	152	
patients	treated	with	radical	irradiation.	The	youngest	patient	was	
26,	the	oldest	76;	mean	age	of	patients	was	62	with	median	of	65.	
Duration	of	pathological	symptoms	varied	from	3	to	14	months;	
it	amounted	 to	7	months	on	average	with	median	of	8	months.	
Twenty	eight	(18.4%)	patients	were	nulliparous,	54	(35.5%)	had	
one	or	two	children,	and	70	(46.1%)	had	three	or	more	children.	
Nineteen	(12.5%)	patients	had	prior	hysterectomy	indicated	for	
uterine	myomas	(16	patients)	or	preinvasive	cancer	(3	patients);	
the	latter,	more	than	10	years	before	PIVC	was	diagnosed.	Pre-
treatment	haemoglobin	(Hg)	level	was	equal	or	lower	than	12g/
dl	 (10.1-12.0g/dl)	 in	 48	 (31.6%)	 patients;	 the	 remaining	 79	
(52.0%)	patients	had	higher	Hg	level	(12.1-15.6g/dl).	Karnofsky	
performance	status	was	rated	80-90	in	73	(48.0%)	patients	and	
60-70	in	79	(52.0%)	patients.		In	80	(52.6%)	cases,	primary	site	
of	PIVC	was	the	upper	third	of	vagina;	in	28	(18.4%),	the	middle	
third;	and	in	44	(29.0%),	the	lower	third.	In	92	(60.5%)	patients,	
primary	focus	of	the	tumour	was	located	on	the	posterior	wall	of	
vagina;	in	38	(25.0%),	on	the	anterior	wall;	and	in	22	(14.5%),	on	
the	lateral	wall.	In	total	in	74	(48.7%)	cases,	the	site	of	primary	
tumour	 was	 the	 posterior	 wall	 of	 the	 upper	 third	 of	 vagina.	
Exophytic	 tumour	 was	 definitely	 the	 most	 often	 macroscopic	
type	observed,	found	in	95	(62.5%)	patients;	next	most	often	was	
infiltrating	tumour	–	52	(34.2%)	cases;	and	the	least	frequently	
recorded	was	multifocal	growth	–	5	(3.3%)	cases.	In	68	(44.8%)	
cases,	1/3	of	vagina	length	was	involved;	in	49	(32.2%),	2/3;	and	
in	35	(23.0%),	more	than	2/3.	
Ninety	five	(62.5%)	patients	were	 in	FIGO	stage	I°	or	 II°;	
35	 (23%),	 in	 stage	 III°;	 and	22	 (14.5%),	 in	 stage	 IV0A.	Using	
available	diagnostic	methods,	distant	metastases	were	 found	 in	
none	of	 the	patients	of	 the	 investigated	group	at	 the	 time	 their	
treatment	 started.	 In	 4	 cases,	 metastases	 in	 inguinal	 lymph	
nodes	were	cytologically	confirmed;	and	 in	13	cases,	based	on	
ultrasound	or	CT	scans,	metastases	 in	regional	 lymph	nodes	of	
pelvis	minor	were	suspected.
Definitely	the	most	frequent	histological	type	of	PIVC	in	the	
investigated	group	was	squamous	cell	carcinoma,	found	in	129	
(84.9%)	cases;	21	(13.8%)	patients	had	adenocarcinoma;	and	2	
(1.3%),	undifferentiated	 cell	 carcinoma.	There	were	4	 cases	of	
clear	cell	adenocarcinoma	in	the	investigated	group,	but	none	of	
them	was	 diethyl-stilbestrol-related.	Well-differentiated	 tumour	
(G1)	was	found	in	29	(19.1%)	patients;	moderately	differentiated	
(G2),	 in	 54	 (35.5%);	 and	 poorly	 differentiated	 (G3),	 in	 69	
(45.4%).
 Streszczenie 
Cel pracy: Celem pracy była ocena czynników prognostycznych w grupie chorych na pierwotnego inwazyjnego 
raka pochwy (PIVC) poddanych radykalnej radioterapii.
Materiał i metody: Przedmiotem analizy była grupa 152 chorych na PIVC poddanych: samodzielnej brachyterapii 
dojamowej (16,5%), brachyterapii dojamowej skojarzonej z teleradioterapią (78,9%) lub samodzielnej teleradiote-
rapii (4,6%). Przeprowadzono analizę zależności pomiędzy wynikami leczenia, a następującymi cechami popu-
lacyjnymi, klinicznymi i mikroskopowymi: wiek, czas trwania objawów chorobowych, liczba porodów, uprzednio 
wykonana histerektomia, poziom hemoglobiny, stopień sprawności wg skali Karnofskiego, punkt wyjścia raka w 
obrębie pochwy, długość pochwy zajętej przez raka, zaawansowanie raka wg FIGO, postać makroskopowa guza, 
postać mikroskopowa i zróżnicowanie raka.
Wyniki: 5 lat bez objawów nowotworu przeżyło 46,1% chorych (70/152). Statystycznie znamiennie wyższe bezob-
jawowe  przeżycie 5-letnie  uzyskano u chorych poniżej 60 roku życia, w stopniu sprawności Karnofskiego 80-90, 
chorych na PIVC w I0 i II0 zaawansowania oraz chorych na PIVC G1 i G2. W analizie wielocechowej niezależnymi, 
korzystnymi czynnikami prognostycznymi były: wiek poniżej 60 lat oraz I0 i II0  zaawansowania raka wg FIGO.
Wnioski: Niezależnymi czynnikami prognostycznymi u chorych na PIVC poddanych radykalnej radioterapii są wiek 
i stopień zaawansowania raka wg FIGO. 
 Słowa kluczowe: rak pochwy / radioterapia / czynniki prognostyczne / 
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All	patients	of	 the	group	were	 treated	with	 radiation	only.	
Hundred	forty	five	(95.4%)	patients	received	intracavitary	LDR	
brachyterapy	with	Ra-226	 (manual	 loading)	or	Cs-137	 sources	
(Selectron	 LDR/MDR	 afterloader).	 Hundred	 twenty	 seven	
(83.5%)	patients	underwent	external	radiation	therapy,	including	
58	(45.7%)	treated	with	Co-60	teletherapy	unit;	the	remaining	69	
(54.3%),	with	10MV	or	6MV	linear	accelerator.	Four-field	box	
technique	(anterior,	posterior	and	two	opposite	lateral	fields)	was	
applied	with	the	total	dose	to	the	pelvis	minor	area	of	50	Gy	in	25	
fractions	in	5	weeks.	
For	25	(16.5%)	patients,	intracavitary	brachytherapy	was	the	
only	 treatment	advised;	all	of	 them	were	 in	FIGO	stage	I°	and	
the	primary	tumour	did	not	exceed	0.5	cm	in	thickness	and	2	cm	
in	its	largest	dimension.	Total	radiation	dose	to	primary	tumour	
calculated	at	 the	depth	of	0.5	cm	from	vaginal	mucosa	surface	
was	65-70	Gy.	Fourteen	(9.2%)	patients	in	stage	I°	with	primary	
tumour	of	the	thickness	larger	than	0.5cm,	all	the	patients	in	stage	
II°	and	III°	(91	=	59.8%),	as	well	as	15	(9.9%)	patients	in	stage	
IVa°	 received	 intracavitary	 brachytherapy	 in	 combination	with	
external	radiation	therapy.	Brachytherapy	dose	to	the	infiltration	
base	was	65-70Gy;	external	radiotherapy	dose	to	the	pelvis	minor	
was	 50Gy	 given	 in	 25	 fractions	 during	 5-week	 period.	 Seven	
(4.6%)	PIVC	patients	in	stage	IVa°,	for	whom	it	was	technically	
not	 possible	 to	 perform	 intracavitary	 brachytherapy	 due	 to	 the	
local	 extent	 of	 neoplastic	 disease	 in	 vagina,	were	 treated	with	
external	 radiation	 therapy	 alone.	 Patients	 irradiated	 with	 four-
field	box	technique	to	the	dose	of	50Gy	received	additional	20-
25Gy	boost	using	“shrinking-field	technique”	up	to	total	dose	of	
70-75Gy.	
It	should	be	noted	that	in	case	of	PIVC	patients	with	primary	
tumour	in	the	lower	third	of	vagina,	area	irradiated	with	external	
beams	was	“prophylactically”	extended	to	include	inguinal	nodes.	
Four	 patients	 with	 cytologically	 confirmed	 PIVC	 metastases	
in	 inguinal	 lymph	 nodes	 were	 given	 additional	 15-20Gy	 dose	
(“boost”)	 to	 that	 area	 using	 smaller	 fields	 of	 15MeV	 electron	
beams.	Detailed	description	of	external	radiation	therapy	as	well	
as	 intracavitary	 brachytherapy	 techniques	 employed	 in	 COOK	
has	been	presented	in	previous	works	[13,	21].	
The	criterion	to	assess	radiotherapy	effectiveness	was	5-year	
disease-free	 survival,	 counting	 from	 the	 day	 irradiation	 was	
started.	All	 the	 patients	were	 followed	 up	 for	 at	 least	 5	 years,	
unless	 patient	 died	 within	 that	 period.	 The	 mean	 follow-up	
period	was	8.7	years	(6.0-26.1).	Log-rank	test	by	Peto	et all. [22] 
was	used	to	evaluate	significance	of	the	differences	found	in	the	
research	material.	Survival	probability	was	estimated	using	 the	
Kaplan-Meier	method	[23].	Statistical	significance	level	was	set	
at	p	≤	0.05.	Influence	of	selected	factors	on	patient	survival	times	
was	assessed	using	Cox’s	proportional	hazard	model	[24].	
Results 
Of	the	152	patients	in	the	investigated	group,	70,	i.e.,	46.1%	
were	disease-free	for	5	years.	Six	(3.9%)	patients	died	during	the	
5-year	 follow-up	with	 no	 evidence	 of	 PIVC:	 3,	 of	myocardial	
infarction;	 2,	 of	 cerebral	 haemorrhage;	 1,	 of	 acute	 pulmonary	
infection;	 and	2,	 (1.3%),	 of	 secondary	 cancer	 (malignant	brain	
glioma	 and	 non-small	 cell	 lung	 cancer).	 The	 remaining	 74	
(48.7%)	patients	died	of	PIVC.	
Table	I	presents	the	relationship	between	treatment	outcome	
and	demographic,	clinical	and	histopathological	features.	
Results	of	single	factor	analysis	presented	 in	Table	I	show	
that	 the	 following	 features	were	 of	 none	 significant	 impact	 on	
the	therapy	results,	hence	were	not	prognostic	factors	for	5-year	
disease-free	survival:	duration	of	pathological	symptoms,	number	
of	births	given,	prior	hysterectomy,	pre-treatment	haemoglobin	
level,	 primary	 tumour	 location	 in	 vagina,	 length	 of	 vagina	
involved,	tumour	gross	appearance,	and	histological	type.
Significantly	higher	5-year	disease-free	survival	was	observed	
in	patients	below	60	years	old,	with	Karnofsky	performance	status	
score	of	80-90,	diagnosed	with	PIVC	in	FIGO	stage	I°	or	II°,	and	
with	well	or	moderately	differentiated	tumour	(G1,	G2).
Cox	 multifactoral	 analysis	 showed	 that	 independent	
favourable	prognostic	factors	for	5-year	disease-free	survival	in	
the	investigated	group	of	152	PIVC	patients	treated	with	radical	
irradiation	were	age	below	60	and	FIGO	stage	I°	or	II°.	
Discussion
Profile	of	 the	 investigated	group	 in	 terms	of	demographic,	
clinical	 and	 histopathological	 features	 is	 clearly	 similar	 to	
majority	of	presented	in	the	literature	groups	treated	with	radical	
irradiation.	 It	 particularly	 applies	 to	 the	 following	 features:	
patient	age,	duration	of	pathological	symptoms,	number	of	births	
given	 [1,	14,	20,	25-27];	 tumour	 location	 in	vagina	 [1,	6,	7,	9,	
19,	28];	length	of	vagina	involved	[1,	2,	8,	13,	27];	histological	
type	[1,	3,	6,	7,	9,	19,	26,	29];	and	tumour	grade	[1,	2,	4-6,	12,	
17,	18,	26,	27,	30].	In	2004,	Hacker	presented	his	compilation	of	
selected	13	reports	on	PIVC	published	between	1982	and	2001,	
describing	1501	patients	in	total;	26.3%	of	them	were	diagnosed	
with	 PIVC	 in	 FIGO	 stage	 I°;	 37.4%,	 in	 stage	 II°;	 23.5%,	 in	
stage	III°;	and	12.8%,	in	stage	IV0	[31].	The	group	of	152	PIVC	
patients	discussed	 in	 this	paper	has	a	clinical	profile	 similar	 to	
that	presented	by	Hacker:	 stage	 I°	–	25.7%,	 stage	 II0	–	36.8%,	
stage	III°	–	23.0%,	stage	IVa°	–	14.5%.
In	 the	 investigated	group	of	152	 radically	 irradiated	PIVC	
patients,	 5-year	 disease-free	 survival	 was	 observed	 in	 70,	 i.e.,	
46.1%	of	patients.	In	the	comprehensive	reports	by	Kosary	(1994),	
Creasman	 et all.	 (1998),	 and	 Hacker	 (2004),	 5-year	 survival	
for	 the	whole	group	of	PIVC	patients	were	51.0%,	52.2%,	and	
45.5%,	respectively	[3,	31,	32].	Hence,	the	results	achieved	in	the	
investigated	group	are	in	line	with	the	reported	in	the	literature.	
Multifactoral	analysis	of	prognostic	factors	in	the	investigated	
group	 of	 152	 PIVC	 patients	 treated	 with	 radical	 radiotherapy	
showed	 that	patient	age	and	FIGO	stage	of	carcinoma	were	of	
independent	 and	 statistically	 significant	 impact	 on	 treatment	
results.
In	 the	 investigated	group,	5-year	disease-free	survival	was	
observed	 in	 64.3%	of	 patients	 younger	 than	 60,	 and	 30.5%	of	
patients	aged	60	or	older.	Straight	majority	of	the	authors	agree	
that	age	is	an	independent	prognostic	factor	in	the	group	of	PIVC	
patients	treated	with	radiotherapy;	the	younger	age,	the	better	is	
the	prognosis	[5,	6,	13,	14,	28-30,	32-34].	In	the	group	presented	
by	 Gesta	 et all.,	 65%	 of	 women	 <70	 and	 only	 40%	 of	 older	
patients	were	cured	of	cancer	[35].	Vavry	et all.	reported	5-year	
survival	 for	 50%	 and	 34%	 of	 patients	 younger	 and	 older	 than	
60,	respectively	[36].	In	the	study	by	Kojs	et all.,	5-year	disease-
free	 survival	was	 observed	 in	 63.2%	of	 patients	 <60	 and	 only	
in	 25%	 of	 older	 patients	 [34];	 Frank	 et all.	 reported	 50%	 and	
63.2%	survival,	respectively	[28].	In	the	research	by	Hellman	et 
all.,	multifactoral	analysis	showed	 that	–	apart	 from	carcinoma	
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Table. I. Relationship between treatment outcome and demographic, clinical, and histopathological features in the group of 152 PIVC patients.
Demographic, clinical and histopathological 
features
Number of 
patients treated
5-year disease-free survival
Number of 
patients %
**   Age:
< 60 years old
≥ 60 years old
70
82
45
25
64.3
30.5
Duration of pathological symptoms: 
< 7 months 
≥ 7 months 
79
73
37
33
46.8
45.2
Number of births given:
none
1 or 2
3 or more
28
54
70
13
25
32
46.4
46.3
45.7
Prior hysterectomy:
no 
yes
133
19
62
8
46.6
42.1
Haemoglobin level (g/dl):
≤ 12g/dl
> 12 g/dl
48
104
21
49
43.8
47.1
* Karnofsky performance status score:
80-90
60-70
73
79
40
30
54.8
38.0
Primary site of tumour in vagina (longitudal 
location):
upper third
middle third
lower third 
80
28
44
39
12
19
48.8
47.9
43.2
Primary site of tumour in vagina (wall involved):
posterior wall
anterior wall
lateral wall
92
38
22
44
16
10
47.8
42.1
45.5
Primary site of tumour in vagina:
upper third, posterior wall
other locations
74
78
39
31
52.7
39.7
Length of vagina involved:
1/3
2/3
> 2/3
68
49
35
32
23
15
47.1
46.9
42.9
** FIGO stage:
I0
II0
III0
IVa0
39
56
35
22
30
29
9
2
76.9
51.8
25.7
9.1
Primary tumour gross appearance:
exophytic
infiltrating
multifocal 
95
52
5
44
24
2
46.3
46.2
40.0
Histopathology:
squamous cell carcinoma
adenocarcinoma
undifferentiated cell carcinoma 
129
21
2
61
9
-
47.3
42.9
-
*  Tumour grade:
G1
G2
G3
29
54
69
17
28
25
58.6
51.9
36.2
Total 152 70 46.1
* difference statistically significant, log-rank test, p<0.05
** difference statistically significant, log-rank test, p<0.01
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stage	and	primary	tumour	size	–	age	was	the	third	independent	
prognostic	 factor	 [5].	Worse	 survival	 of	 patients	 >65	was	 also	
observed	by	Wu	et all.	in	their	American	population	research	[14].	
Malmstrőma	et all.	recorded	5-year	survival	amounting	to	43%	
in	 the	group	of	patients	younger	 than	70,	and	21%	for	patients	
older	than	70	[30].	The	results	of	the	de	Crevoisier	et all.	research	
show	 that	 age	 was	 of	 prognostic	 significance	 for	 the	 overall	
survival,	but	had	no	impact	on	the	5-year	disease-free	survival	in	
their	investigated	group	of	patients	[4].	Similar	observations	were	
made	by	Perez	et all.	as	well	as	Dixit	et all.	[12,	37].	Some	of	the	
authors	question	independent	prognostic	significance	of	age	and	
emphasize	that	its	impact	on	treatment	results	is	revealed	mainly	
in	single	factor	analyses	[3,	8,	12,	17,	18,	38].	
In	 the	group	of	PIVC	patients	managed	with	 radiotherapy,	
FIGO	stage	of	carcinoma	is	the	primary	prognostic	factor,	never	
raising	doubts	in	the	literature	[2-6,	8,	13,	16-20,	27,	28,	30,	33-
41].	Five-year	survival	is	observed	in	60-95%	of	stage	I0	patients;	
35-80%,	of	stage	II0;	29-60%,	of	stage	III0;	and	0-25%,	of	stage	
IV0	[2-4,	6,	8,	12,	19,	26,	28,	34].	In	1994	in	his	comprehensive	
analysis	 of	 1973-87	SEER	cases	 including	669	PIVC	patients,	
Kosary	reported	5-year	survival	for	64%	of	patients	in	stage	I0;	
53.5%,	in	stage	II0;	36%,	in	stage	III0;	and	18%,	in	stage	IV0	[32].	
In	the	NCDB	(National	Cancer	Data	Base)	report	by	Creasman	et 
all.,	5-year	survival	in	the	group	of	729	patients	treated	between	
1984	and	1994	was	observed	in	73%	of	patients	in	stage	I0;	59%,	
in	stage	II0;	and	36%,	in	stage	III0	and	IV0	[3].	In	2004	Hacker	
et all.	 summarized	 treatment	 results	 of	 934	 patients	 presented	
in	8	studies	conducted	between	1979	and	2001,	and	found	that	
5-year	survival	in	stage	I0,	II0,	III0,	and	IV0	was	70.3%,	50.8%,	
33.0%,	 and	 17.3%,	 respectively	 [31].	 Indisputable	 differences	
exist	 between	 stage	 IVa	 and	 IVb.	 While	 there	 are	 generally	
no	reports	 in	 the	 literature	on	5-year	survival	 in	stage	IVb,	 the	
survival	rate	in	stage	IVa	amounts	from	0%	to	around	20%	[4,	5,	
12,	19],	and	even	to	30-40%,	as	recorded	by	few	authors	[2,	6].	In	
the	investigated	group,	5-year	survival	was	observed	in	76.9%	of	
PIVC	patients	in	stage	I0;	51.8%,	in	stage	II0;	25.7%,	in	stage	III0;	
and	9.1%,	in	stage	IVA0.
	Apart	from	age	and	FIGO	stage,	there	were	not	found	any	
other	 independent	prognostic	 factors	 in	 the	 investigated	group;	
the	 literature,	however,	presents	 at	 least	 several	other	potential	
factors.
Many	 authors	 underline	 prognostic	 significance	 of	 PIVC	
histological	 type;	 prognosis	 for	 squamous	 cell	 carcinoma	
patients	 is	 supposed	 to	 be	 significantly	 better	 than	 in	 case	 of	
adenocarcinoma	[2,	26,	28,	32,	36].	Comparing	treatment	results	
for	the	both	most	frequent	histological	types	of	PIVC,	Chyle	et 
all.	observed	local	recurrence	during	10-year	follow-up	in	52%	
of	 adenocarcinomas	 vs.	 20%	 of	 squamous	 cell	 carcinomas;	
distant	metastases,	in	48%	vs.	10%;	and	10-year	survival,	in	20%	
vs.	 50%	 of	 patients,	 respectively	 [2].	 Stryker	 et all.	 observed	
5-year	survival	in	50%	of	adenocarcinoma	patients	and	in	68%	
of	squamous	cell	carcinoma	patients;	Otton	et all.	reported	22%	
and	 69%,	 respectively	 [26,	 42].	 Finally	 in	 2005,	 Frank	 et all. 
observed	higher	percentage	of	both	local	control	(81%	vs.	39%)	
and	overall	survival	(58%	vs.	34%)	in	the	group	of	squamous	cell	
carcinoma	patients	[28].	It	should	be	noted,	however,	that	equally	
many	 researchers,	 including	 also	 authors	 of	 this	 work,	 found	
no	 significant	 independent	 correlations	 between	 radiotherapy	
outcome	and	histological	type	of	PIVC	[5,	6,	13,	18,	27,	29,	30].	
Prognostic	significance	of	tumour	grade	gives	rise	to	much	
controversy.	 Some	 authors	 strongly	 suggest	 better	 curability	
in	 the	 group	 of	 PIVC	 patients	 with	 well	 differentiated	 (G1,	
G2)	 tumour	[2,	6,	12,	13,	26,	34,	36,	37,	42,	43].	 In	 the	group	
presented	by	Malmström	et all.,	5-year	survival	was	observed	in	
57%,	32%,	and	17%	of	PIVC	patients	in	grade	G1,	G2,	and	G3,	
respectively	[30].	In	the	material	analyzed	by	Vavry	et all.,	62.5%	
of	G1	and	G2	patients,	41.5%	of	G3	patients,	and	34.9%	of	G4	
patients	 were	 reported	 as	 disease-free;	 in	 the	 paper	 by	 Dixita	
et all.,	 62.5%,	 of	G1	 and	G2;	 and	 38.5%,	 of	G3	 and	G4	 [36,	
37].	Multifactoral	analysis	by	Perez	et all.	 showed	that	 tumour	
histologic	 grade	was	 a	 prognostic	 factor	 for	 distant	metastasis	
[12].	Kojs	et all.	recorded	5-year	disease-free	survival	in	57.9%	
of	grade	G1	and	G2	patients,	and	only	in	18.4%	of	grade	G3	and	
G4	patients;	Otton	et all. reported	69%	and	40%	in	G1-G2	and	G3	
patients,	respectively	[34,	42].	Many	authors,	including	authors	
of	this	work,	did	not	show	PIVC	tumour	grade	to	be	independent	
prognostic	factor	[4-6,	17,	18,	27,	38].	
Some	researchers	emphasize	that	PIVC	site	in	the	proximal	
part	 of	 vagina	 provides	 better	 prognosis	 than	 distant	 tumour	
location	[2,	13,	16].	Ali	et all.	observed	5-year	overall	survival	
in	81%	of	patients	diagnosed	with	primary	tumour	in	proximal	
part	of	vagina	and	only	 in	41%	 in	case	of	distal	 location	 [16].	
More	 detailed	 analysis	 of	 clinical	material	 shows	 that	 the	 best	
prognosis	is	related	with	tumour	location	in	upper	third	of	vagina;	
the	worst,	with	tumour	in	the	lower	third	[2,	16,	18,	27-29,	36,	
37].	Kucera	 and	Vavra	 observed	 5-year	 survival	 rates	 of	 60%,	
37.5%,	and	37%	for	PIVC	location	in	upper,	middle	and,	lower	
third	of	vagina,	respectively;	Chyle	et all.	–	60%,	51%,	and	29%;	
and	 Pingley	 et all.	 –	 100%,	 85%,	 and	 45%	 [2,	 27,	 44].	Vavra	
et all.	cured	61%	of	patients	with	 tumour	 in	 the	upper	 third	of	
vagina	 and	 only	 33.3%	 with	 tumour	 in	 the	 lower	 third	 [36].	
However,	considerable	number	of	authors,	including	authors	of	
this	study,	believes	 that	primary	 tumour	 location	within	vagina	
is	not	an	independent	prognostic	factor	[4-6,	12,	13,	26,	28,	38,	
41,	42].	
In	 the	 literature,	 there	 are	 also	 other	 prognostic	 factors	
mentioned	resulting,	however,	from	single	factor	analyses	only,	
e.g.	primary	tumour	size	[2,	5,	6,	8,	19,	20,	30,	33,	39];	extent	of	
vaginal	involvement	[2,	8,	13,	19,	27,	36,	37,	44];	primary	tumour	
gross	appearance	(exophytic	vs.	infiltrating	ulcerating)	[12,	45];	
pre-treatment	haemoglobin	level	[8,	41];	prior	hysterectomy	[2,	
41];	accidental	diagnosis	of	PIVC	in	patients	with	no	symptoms	
[36,	44];	etc.
Conclusions
Independent	favourable	prognostic	factors	in	PIVC	patients	
are	age	below	60	and	FIGO	stage	I°	and	II°.	
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